These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date, and reported results 2004-000020-32 The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Severe Hypertension bad-data
Ongoing, reported early 2004-000022-75 Irbesartan Versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk not-yet-due
Reported results 2004-000033-11 The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Patients with Moderate Hypertension 2005-06-30 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-000119-24 Protocol CA165020: A Randomized, Two -Cohort Phase II Study of Two Doses of BMS-275183 Given On a Weekly Schedule in Patients with Pre-Treated Non- Small Cell Lung Cancer 2006-03-29 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-000202-49 Efficacy of Aripiprazole in combination with Valproate or Lithium in the treatment of mania in patients with Bipolar I disorder partially nonresponsive to valproate or lithium monotherapy 2007-12-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-000822-58 A double blind randomized study of Clopidogrel 75 mg/d versus placebo on a background of ASA 75-100 mg/d, in peripheral arterial disease (PAD) patients receiving a unilateral below knee by-pass graft 2009-08-05 bad-data
Completed, but no date, and reported results 2004-000903-17 A Prospective, Multicenter, Open-Label Study to Evaluate the Effectiveness and the Effect on Cognitive Functioning of a Treatment with Aripiprazole in a Broad Range of Schizophrenic Patients bad-data
Listed as ongoing, but also has a completion date and reported results 2004-000922-59 A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination with Methotrexate in Controlling Disease Activity in Subjects with R... 2009-07-03 bad-data
Reported results 2004-001128-19 A Phase 2 Randomized, Double Blinded (BMS-562247 and enoxaparin), Active-Controlled (enoxaparin and warfarin), Parallel-Arm, Dose Response Study of the Oral Factor Xa Inhibitor BMS-562247 in Subjects ... 2005-11-24 due-trials
Reported results 2004-001181-41 A Prospective, Multicenter, Open-Label Study of Aripiprazole in the Management of Patients with Schizophrenia in General Psychiatric Practices 2007-02-07 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-002515-89 A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate 2008-04-09 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-002516-28 A Phase II Study of BMS-354825 in Subjects with Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate 2008-03-26 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-002517-36 A Phase II Study of BMS-354825 in Subjects with Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Me... 2007-12-07 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-002601-69 A phase II study to determine the activity of BMS-354825 in subjects with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia who have disease that is resistant to high dose imatin... 2008-04-07 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-002620-18 A multi-national randomized, double-blind exploratory study of Abatacept versus placebo in preventing the development of rheumatoid arthritis in adults subjects with undifferentiated inflammatory arth... 2008-04-04 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-002740-10 A phase IV, open-label, randomized, multicenter trial assessing a reyataz-based substitution approach in the management of lipodystrophy syndrome. 2008-06-25 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-002880-26 A Phase IV, multi-center, cross-sectional study to evaluate the I50L substitution among subjects experiencing virologic failure on a HAART regimen containing atazanavir ATV 2009-03-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-002974-48 Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - EXTended Criteria Donors (BENEFIT-EXT) Amendment 1 and Revised protocol Number:01 (Incorporates Amendment... 2014-09-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-003635-31 Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT). 2015-04-17 bad-data
Reported results 2004-004051-19 A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy with Glucocorticosteroids vs. Placebo plus Glucoco... 2008-10-31 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-004450-96 A Randomized Multi-center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Dise... 2008-03-31 bad-data
Reported results 2004-004604-20 An Open-Label, Two-Stage, Fixed-Dose, Multicenter Phase II Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin’s Disease 2008-06-23 due-trials
Reported results 2004-005040-27 An Open-Label, Phase II Extension Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin’s Disease Previously Treated in Protocol MDX060-03 2007-07-25 due-trials
Reported results 2004-005059-32 A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Peptide Vaccine Monotherapy in HLA-A*0201-Positive Pat... 2009-08-27 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-005102-68 A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects with Active Rheumatoid Arthritis on Background Non-Biologic DMARDs W... 2009-08-11 bad-data
Trial is outside EEC, and reported results 2005-000443-28 A Phase III, Multi-Center, Multi-National, Randomized, Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents with Active Polyarticular Juvenile Rheumatoid Arth... bad-data
Listed as ongoing, but also has a completion date and reported results 2005-000472-40 A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are Experiencing Insufficient Efficacy with... 2007-04-06 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-000614-12 Irbesartan in the treatment of Hypertensive Patients with Metabolic Syndrome. 2007-02-01 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-000784-26 A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated with Abatacept plus Methotrexate Co... 2009-10-08 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-000865-21 A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing the Efficacy of a Treatment Maintenance Phase with Unboosted vs. Boosted Reyataz After an Induction Phase with Reyataz and Ritonavir in ... 2008-01-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-001169-32 A randomized two-arm, multicenter, open-label phase III study of BMS-354825 administered orally at a dose of 70 mg twice daily or 140 mg once daily in subjects with chronic myeloid leukemia in acceler... 2013-06-30 bad-data
Completed, but no date, and reported results 2005-001233-16 Efficacy of Aripiprazole in Combination with Lithium or Valproate in the Long Term Treatment of Mania in Patients with Bipolar I Disorder Partially Nonresponsive to Lithium or Valproate Monotherapy bad-data
Reported results 2005-001294-99 A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase... 2014-07-14 due-trials
Reported results 2005-001388-71 A phase 2 randomized, parallel-arm study of oral direct factor Xa-inhibitor apixaban and low molecular weight heparin or fondaparinux with a vitamin K antagonist in subjects with acute symptomatic dee... 2007-03-27 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-001463-64 A phase II study of intravenous IV vinflunine in patients with locally advanced or metastatic transitional cell carcinoma TCC of the urothelium. 2007-11-05 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-001809-25 A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study on the Effect on Weight of Adjunctive Treatment with Aripiprazole in Patients with Schizophrenia 2007-09-27 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-001895-11 A 96 Week Phase IIIB Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir ATV/RTV with Lopinavir/ritonavir LPV/RTV , Each in Combination with Fixed Dose Tenofovir-Emtricitabin... 2008-10-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-002051-41 A multi-center single arm phase II study of MDX-010 BMS-734016 monotherapy in patients with previously treated unresectable stage III or IV melanoma. 2007-07-24 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-002126-64 An Exploratory Study to Determine Potential Predictive Markers of Response and/or Toxicity in Patients with Unresectable Stage III or IV Malignant Melanoma Randomized and Treated with Ipilimumab (MDX-... 2008-02-03 bad-data
Reported results 2005-002678-31 Randomized, Double-Blind, Placebo-Controlled Phase II Study Comparing the Safety of Ipilimumab Administered With or Without Prophylactic Oral Budesonide (Entocort EC) in Patients with Unresectable Sta... 2007-08-01 due-trials
Ongoing, reported early 2005-002809-23 Electrophysiological effects of Irbesartan in patients with paroxysmal AF Efectos electrofisiológicos del Irbesartán en sujetos con FA paroxística not-yet-due
Ongoing, reported early 2005-002848-25 Protocol Title: A Phase IV, Multi-Center, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate The Analgesic Efficacy And Safety of IV Paracetamol Versus Placebo in subjects with postoperat... not-yet-due
Listed as ongoing, but also has a completion date 2005-002882-35 Phase I study of Src/Abl tyrosine kinase inhibitor dasatinib [BMS-354825] in children and adolescents with relapsed or refractory leukemia, Protocol ITCC 005. 2019-05-22 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-003265-16 A Randomized, Double-Blind, Multi-center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma 2007-07-31 bad-data
Reported results 2005-003284-22 Randomized, Observational Study of Entecavir to Assess Long-term Outcomes Associated with Nucleoside/Nucleotide Monotherapy for Patients with Chronic HBV Infection: The REALM Study 2016-10-26 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-003733-40 A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma TCC of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcit... 2008-07-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-004338-42 A Phase 2, Placebo-Controlled, Randomized, Double-Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban In Patients with a Recent Acute Coronary Syndrome 2008-05-27 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-004575-37 A Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocortic... 2011-07-22 bad-data
Reported results 2005-005022-31 Effect of a High-Fat or a Light Meal Relative to Fasting Conditions on the Pharmacokinetics of Atazanavir when Administered with Ritonavir in Healthy Subjects 2006-05-16 due-trials
Reported results 2005-005099-33 A Three Cohort Phase II Trial of BMS-275183 Given Orally on a Twice Weekly Schedule in Pretreated Locally Advanced or Metastatic NSCLC Patients 2007-01-29 due-trials
Ongoing, reported early 2005-005119-76 Phase IIIb Multicenter, Single Arm, Open-label Pilot Study to Evaluate the Effectiveness and Safety of Maintenance with Atazanavir/ritonavir as Single Enhanced Protease Inhibitor Therapy in HIV-Infect... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2005-005153-22 An open-label, randomized study of dasatinib vs. high-dose 800 mg imatinib in the treatment of subjects with chronic phase chronic myeloid leukemia who have had a suboptimal response after at leas... 2010-01-20 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-005238-11 Belatacept Conversion Trial in Renal Transplantation 2013-06-03 bad-data
Trial is partly outside EEC, and reported results 2005-005816-26 Evaluation of the Pharmacokinetics, Safety, Tolerability and Efficacy of Entecavir (ETV) in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-Positive. 2017-09-04 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-006082-14 A Multi-center, Randomized, Double-blind, Two-Arm, Phase III Study in Patients with Untreated Stage III Unresectable or IV Melanoma Receiving Dacarbazine Plus 10mg/kg of Ipilimumab MDX-010 vs. D... 2013-10-18 bad-data
Reported results 2005-006083-57 A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010) Extended-Treatment Monotherapy 2014-03-18 due-trials
Reported results 2006-000006-23 A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Metformin IR as Initial Therapy Compared to Saxaglipt... 2008-12-09 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-000421-62 A Comparative Study of Chronic Hepatitis B Subjects Treated with Entecavir Plus Tenofovir Combination Therapy vs Entecavir Monotherapy in Adults who are Treatment-Naïve to Nucleosides and Nucleotides:... 2011-03-11 bad-data
Reported results 2006-000422-31 A Comparative Study of Entecavir vs Adefovir Plus Lamivudine vs Combination Entecavir plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Subjects: The DEFINE Study 2012-06-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-000453-22 Study of the Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection 2011-03-10 bad-data
Ongoing, reported early 2006-001012-68 A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally At A Dose of 800 mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients wi... not-yet-due
Completed, but no date 2006-001279-39 A Phase II Study of Dasatinib (BMS-354825) in Subjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant or... bad-data
Listed as ongoing, but also has a completion date and reported results 2006-001921-25 A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as first Line Therapy for Locally Recurrent or Metastatic Breast Cancer 2009-11-02 bad-data
Ongoing, reported early 2006-002045-36 Phase II Study of Dasatinib BMS-354825 for Advanced Triple-negative Breast Cancer not-yet-due
Listed as ongoing, but also has a completion date and reported results 2006-002147-91 A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Nonvalvula... 2011-05-25 bad-data
Reported results 2006-002161-39 A Phase 3 Randomized, Double-Blind, Active-Controlled (Enoxaparin), Parallel Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Knee R... 2008-05-28 due-trials
Ongoing, reported early 2006-002178-23 Phase II Study of Dasatinib BMS-354825 for Advanced Estrogen/Progesterone Receptor-Positive or Her2/neu-Positive Breast Cancer not-yet-due
Listed as ongoing, but also has a completion date and reported results 2006-002205-31 Phase II Study of Dasatinib BMS-354825 for Androgen-Deprived Progressive Prostate Cancer 2009-02-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-003047-24 A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women with Early Stage Breast Cancer Not Overexpressing H... 2009-12-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-003114-17 A randomized,open-label,multicenter, parallel-group study of belatacept-based corticosteroid-free regimens in renal transplant 2012-08-08 bad-data
Ongoing, reported early 2006-003163-31 Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine with or without Tenofovir on the Pharmacokinetics of Atazanavir when given with Ritonavir in HIV-Infected Subjects.... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2006-003371-13 A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohn’s Disease (... 2009-08-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-003604-19 A Phase III, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Ulcerative Coli... 2009-11-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-003674-96 A phase 3 Randomized, Double-blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of venous thromboembolism in acutely III medical subjects during and follo... 2011-05-18 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-003768-67 A Phase III Multicenter, Randomized, Double-Blind, placebo-controlled Study to Assess short-term changes in synovitis and structural damage outcomes in subjects with active Rheumatoid Arthritis and in... 2010-05-25 bad-data
Listed as ongoing, but also has a completion date and reported results 2006-005351-14 A Phase 3, Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery 2009-09-05 bad-data
Reported results 2006-005712-27 An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL) vs. standard Dose Imatinib (400 mg) in the Treatment of Subjects with Newly Diagnosed Chronic Phase Philadelphia Chromosom... 2015-12-22 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-006896-19 A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallelgroup,Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Kne... 2009-01-27 bad-data
Ongoing, reported early 2007-000416-91 A Phase I/II, Ascending, Multi-Dose Study of BMS-663513, An Agonistic Anti-CD137 Monoclonal Antibody, Administered Every Three Weeks to Patients with Metastatic or Locally Advanced Solid Malignancies.... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-000713-11 An Exploratory, Multi-center, Open-Label, Single-Arm study to evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent (DECADES) on Inflammatory and Platelet Activation Markers in S... 2008-06-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-000721-21 Randomized Phase II study of Ixabepilone Plus Trastuzumab vs. Docetaxel Plus Trastuzumab in Female Subjects with Her2+ Locally Advanced and/or Metastatic Breast Cancer 2011-11-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-001217-42 A 16-Week, Multicenter, Randomized, Open-label Study to Assess the Effects of Aripiprazole versus other Atypical Antipsychotics in the Treatment of Schizophrenic Patients with Metabolic Syndrome 2009-03-17 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-001256-39 A Randomized, Double-Blind, Parallel, Three Arm, Multicenter, Phase II Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Taxol/Paraplatin (Paclitaxel/Carboplatin)... 2013-07-31 bad-data
Reported results 2007-001269-14 A Comparative Study of the Antiviral Efficacy and Safety of Entecavir Plus Tenofovir versus Adefovir Added to Continuing Lamivudine in Adults with Lamivudine Resistant Chronic Hepatitis B Virus Infect... 2009-02-03 due-trials
Exempt, with results Terminated 2007-001432-31 A Phase 1/2a, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects with Advanced Cancer. not-yet-due
Exempt, with results Terminated 2007-001433-34 A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects with Advanced Cancer. 2009-12-10 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2007-001557-26 Apixaban Versus Acetylsalicyclic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double Blind Trial + A... 2018-05-25 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-001974-10 Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, doubleblind Phase 3 trial of the EORTC M... 2018-11-26 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-002125-68 Evaluation of Belatacept as First-line Immunosuppression in De Novo Liver Transplant Recipients 2011-01-21 bad-data
Reported results 2007-002544-25 A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (anti-CXCL10 Human Monoclonal Antibody) in Subjects with Active Ulcerative Colitis 2009-09-14 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-003624-37 Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who are Experiencing Clinical Benefit on Current START, CA180039, or CA180043 Protoc... 2014-12-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-003993-24 A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or Stage IV Melanoma 2009-10-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-004138-17 Ensayo Clínico fase 3, aleatorizado, en régimen abierto de Tanespimicina (KOS-953) más Bortezomib en comparación con Bortezomib solo, en pacientes con Mieloma Múltiple en primera recaída. 2009-12-14 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-004241-15 A Phase IIB, Multi-Dose, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis. 2011-01-19 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-004953-27 A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM. 2012-08-24 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-005097-31 A Blinded, Randomized, Phase 1/2 Study of Brivanib Alaninate vs. Placebo in Combination with Erbitux and Irinotecan in K-Ras wild type Subjects with Metastatic Colorectal Cancer. 2012-12-21 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-005209-23 Randomized Phase II of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects with Triple Negative (ER, PR, Her2 negative) Locally Advanced non-resectable and/or ... 2011-05-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-005434-37 A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects with Rheumatoid Arthrit... 2014-09-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-005959-42 A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Patien... 2012-10-05 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-007867-25 A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism 2013-03-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-000087-16 A randomized Discontinuation Study of Brivanib alaninate (BMS-582664) versus Placebo in Subjects with Advanced Tumors. 2013-12-05 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-000170-20 A Randomized, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects with Rheumatoid Arthritis Having an Inadequate ... 2009-09-30 bad-data
Reported results 2008-000701-11 A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer 2015-07-31 due-trials
Reported results 2008-000976-26 A 4-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate The Efficacy and Safety of Saxagliptin in Comparison to Placebo as Add-on Treatment to Metformin XR in Sub... 2009-02-27 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-000977-39 A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Subjects With Advanced Non-Small Cell Lung Cancer 2011-09-02 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-001089-10 A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination with Metformin in Subjects with Typ... 2010-11-08 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-001523-57 Estudio abierto y multicéntrico de evaluación de la respuesta temprana a abatacept con metotrexato de fondo mediante ecografía Power-Doppler en pacientes con artritis reumatoide activa y respuesta ins... 2011-10-28 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-001921-33 A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase 2/3 Trial to Evaluate the Glycemic Efficacy, Renal Safety, Pharmacokinetics, and Pharmacodynamics of Dapagliflozin in... 2011-06-21 bad-data
Trial is partly outside EEC, and reported results 2008-002260-33 A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or with Ph+ Leukemias Resistant or Intolerant to Imatinib bad-data
Listed as ongoing, but also has a completion date and reported results 2008-003183-19 A Randomized, Double-Blind, Multi-Center Phase 2 Trial of Exemestane (Aromasin) plus Dasatinib versus Exemestane plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer after Disease Progres... 2012-12-14 bad-data
Reported results 2008-003314-97 A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxe... 2015-07-03 due-trials
Ongoing, reported early 2008-003364-19 A Multicenter, Randomized, Open-Label, Active-Controlled Pilot Study to Evaluate the Safety and Antiretroviral Activity of Unboosted Atazanavir BID Plus Raltegravir BID and Boosted Atazanavir QD in Co... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2008-003533-24 A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma. 2013-09-26 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-004691-44 A Double-Blind, Randomized, Parallel, Two-Arm Phase II Trial of BMS-690514 versus Erlotinib in Previously Chemotherapy Treated Non-Small Cell Lung Cancer Patients Estudio Fase II doble ciego, aleatori... 2011-07-01 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-005084-34 A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed or... 2017-08-29 bad-data
Reported results 2008-005929-11 A Multicenter, Randomized Double-Blind Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Mild to Moderat... 2010-06-07 due-trials
Ongoing, reported early 2008-006561-89 A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) versus Bevacizumab plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Canc... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2008-007167-16 A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who Have... 2014-02-24 bad-data
Reported results 2008-007768-41 A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer with ... 2013-08-28 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-008298-77 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects with a Recent Acute Coronary Syndrome 2011-03-04 bad-data
Reported results 2008-008715-26 A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients with Unresectable Hepatocellular Carcinom... 2018-01-26 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-010067-16 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal Alz... 2013-07-09 bad-data
Ongoing, reported early 2009-010149-29 A Phase 2a Study of BMS-790052 in Combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects with Chronic Hepatitis C Virus Genotype 1 Infection not-yet-due
Completed, but no date, and reported results 2009-010221-39 An Exploratory Phase 2 Study to Assess the Effect of Dapagliflozin on Glomerular Filtration Rate (GFR) in Subjects with Type 2 Diabetes who have Inadequate Glycemic and Blood Pressure (BP) Control bad-data
Reported results 2009-010224-25 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2.5 mg Saxagliptin, PO, BID, in Combination with Metformin in Subjects... 2010-02-24 due-trials
Exempt, with results 2009-010572-20 A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects with Advanced and/or Metastatic Solid Tumors not-yet-due
Listed as ongoing, but also has a completion date and reported results 2009-010576-21 Randomized phase II of CCNU versus CCNU-dasatinib in patients with recurrent glioblastoma 2011-05-24 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-013652-69 A Phase 2a/2b study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects with Genotypes 1 and 4 Chronic Hepatitis C Infection. 2012-10-16 bad-data
Reported results 2009-013657-14 Randomized, Open label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects 2010-06-22 due-trials
Exempt, with results 2009-013766-78 A Phase I/II Trial of BMS-754807 in Combination with Trastuzumab (Herceptin®) in Subjects with Advanced or Metastatic Her-2-positive Breast Cancer 2012-02-13 not-yet-due
Listed as ongoing, but also has a completion date and reported results 2009-015705-40 A Study of the Safety and Efficacy of Entecavir plus Tenofovir in Adults with Chronic Hepatitis B Virus Infection with Previous Nucleoside/Nucleotide Treatment Failure. 2014-02-18 bad-data
Reported results 2009-016217-23 Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prost... 2015-09-28 due-trials
Trial is partly outside EEC, and reported results 2009-016357-17 A Comparative Study of the Antiviral Efficacy and Safety of Entecavir (ETV) versus Placebo in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-Positive 2018-04-03 bad-data
Trial is partly outside EEC, and reported results 2009-016361-28 A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted with Ritonavir (RTV) Liquid with an Opti... 2017-09-11 bad-data
Listed as ongoing, but also has a completion date and reported results 2009-016622-13 An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole with Lapatinib + Letrozole in Recurrent or Metastatic Breast Cancer Patients Who Are Hormone Receptor Positi... 2010-12-16 bad-data
Reported results 2009-017032-41 An Open-Label, Randomized Study Evaluating a Switch from a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors plus any Third Agent to either a Regimen of Atazanavir/Ritonavir Once Daily and ... 2014-02-18 due-trials
Reported results 2009-017396-19 Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects... 2017-08-22 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-018295-24 A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection 2012-08-29 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-018674-20 A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination with Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy... 2014-12-18 bad-data
Reported results 2010-019378-34 A Phase 2B Study of BMS-790052 in Combination with Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who are Null or Partial Responders to Prior Treatment with Pe... 2012-12-20 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-019797-32 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate 2013-06-14 bad-data
Reported results 2010-019798-13 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with Inadequately Contr... 2013-02-07 due-trials
Ongoing 2010-020347-12 A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma not-yet-due
Trial is partly outside EEC, and reported results 2010-020360-38 A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin (BMS-477118) as Monotherapy in Pediatric Patients ... 2016-04-22 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-020387-38 Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients with Chronic Hepatitis B Virus Infection w... 2013-12-13 bad-data
Reported results 2010-022408-28 A Phase 2B Pilot Study of Short-Term Treatment of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 2 or 3 Infection. 2012-09-13 due-trials
Ongoing 2010-022445-20 A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma. not-yet-due
Reported results 2010-022506-41 A Phase IIb Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-936557 in Subjects with Active Ulcerative Colitis (UC) 2015-03-02 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-022568-11 A Phase 2B, randomized study to evaluate the safety and efficacy of Pegylated Interferon Lambda (BMS-914143) administered with Ribavirin plus a single direct antiviral agent (BMS-790052 or BMS-650032)... 2014-09-24 bad-data
Reported results 2010-022841-93 A Multicenter, Randomized, Double-blind, Active-Controlled Study of the Efficacy and Safety of Flexibly-Dosed BMS-820836 in Patients with Treatment Resistant Major Depression 2013-01-28 due-trials
Reported results 2010-022947-39 Randomized, Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Safety, Tolerability and Effect on Atrial Fibrillation Burden of BMS-914392 in Patients with Paroxysmal Atrial Fibri... 2012-06-13 due-trials
Listed as ongoing, but also has a completion date 2010-023956-99 A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexat... 2015-06-10 bad-data
Listed as ongoing, but also has a completion date and reported results 2010-024371-12 A multicenter, Double-blind 58 week Rollover Study to assess the Safety and Tolerability of BMS-820836 in Patients with Treatment Resistant Major Depression. 2013-10-22 bad-data
Trial is partly outside EEC, and reported results 2010-024537-23 A Prospective Single Arm, Open-Label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder boosted with Ritonavir (RTV) Liquid with an Opti... 2018-01-22 bad-data
Trial is partly outside EEC, and reported results 2010-024568-16 A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination with Metformin IR or Metformin XR in Pediatric Patients... 2016-04-22 bad-data
Trial is partly outside EEC, and reported results 2010-024597-19 Multiple-Dose Study Apixaban in Pediatric Subjects with an Indwelling Central Venous Catheter 2012-10-05 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-000083-10 An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib plus Smoothen Antagonist (BMS-833923) in the Treatment of Subjects with Newly Diagnosed Chronic Phase Philade... 2016-01-25 bad-data
Reported results 2011-000437-36 A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, 2017-05-12 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-000732-29 A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab versus Pemetrexed in Subjects with Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After F... 2013-02-21 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-000778-71 A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depression... 2013-07-23 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-000836-27 An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C 2015-01-12 bad-data
Reported results 2011-000850-48 Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease Sma... 2017-08-04 due-trials
Reported results 2011-000853-22 A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab versus best supportive care following first-line chemotherapy in subjects with unresectable locally ad... 2015-04-02 due-trials
Trial is partly outside EEC, and reported results 2011-001123-20 A Phase 2 Multi-Center, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukem... bad-data
Ongoing, reported early 2011-002024-40 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BMS-817399 in Adults with Active, Moderate to Severe Rheumatoid ... not-yet-due
Reported results 2011-002695-16 A Phase 2, Randomized Study of Bortezomib/dexamethasone With or Without Elotuzumab in Subjects with Relapsed/Refractory Multiple Myeloma. 2017-04-21 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-002793-23 A Phase 3 Evaluation of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotype 4 2014-01-23 bad-data
Completed, but no date 2011-002957-67 A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) in Subjects With Progressive Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Ther... bad-data
Reported results 2011-002981-19 A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-936557 in Subjects with Active Crohn's Diseas... 2014-12-29 due-trials
Reported results 2011-003067-30 A Phase 3, Open Label Study of Safety and Efficacy with BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with Human Immunodeficiency Virus (HIV) and... 2014-09-10 due-trials
Reported results 2011-003128-11 Phase II trial of dasatinib in subjects with advanced cancers harboring DDR2 mutation or inactivating B-RAF mutation 2014-07-23 due-trials
Trial is outside EEC, and reported results 2011-003300-21 A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety of Atazanavir (ATV) Capsule Boosted with Ritonavir (RTV) with an Optimized NRTI Background Therapy, in HIV... bad-data
Reported results 2011-003329-89 A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-lab... 2014-08-05 due-trials
Listed as ongoing, but also has a completion date 2011-004016-29 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Multi-Center Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection in Adults with Active Psoriatic Arth... 2015-06-18 bad-data
Listed as ongoing, but also has a completion date and reported results 2011-004029-28 A Randomized Double-Blind Phase III Study of Ipilimumab Administered at 3 mg/kg vs at 10 mg/kg in Subjects with Previously Treated or Untreated Unresectable or Metastatic Melanoma 2017-08-15 bad-data
Reported results 2011-004237-14 A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C 2014-03-20 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-004695-11 A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepat... 2015-05-15 bad-data
Reported results 2011-004763-72 A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-945429 in Subject... 2013-12-30 due-trials
Ongoing 2011-004792-36 An Open-Label Randomized Phase III Trial of 936558 (Nivolumab) versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) not-yet-due
Reported results 2011-004885-14 A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combinatio... 2014-09-24 due-trials
Reported results 2011-005121-49 Phase 2a Single-Arm Safety Study of Elotuzumab in Combination with Thalidomide and Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma 2016-03-17 due-trials
Ongoing 2011-005132-26 A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy not-yet-due
Trial is outside EEC, and reported results 2011-005225-40 A Randomized, Multi-Center, Parallel Group, Single-Dose, Pharmacokinetics and Pharmacodynamics Study of Dapagliflozin in Children and Adolescents Aged 10 to 17 Years with Type 2 Diabetes Mellitus bad-data
Trial is partly outside EEC, and reported results 2011-005257-31 A Phase 2 Multi-Center, Randomized Conversion Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belatacept Administered to Pediatric Subjects with a Stable Renal Transplant bad-data
Listed as ongoing, but also has a completion date 2011-005287-21 A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatitis C... 2018-03-16 bad-data
Reported results 2011-005293-31 A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in which BMS-914143 was Administered for the Treatment of Chronic Hepatitis C 2014-11-20 due-trials
Reported results 2011-005409-65 A Phase 3 Evaluation of Daclatasvir in Combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatitis C... 2014-10-13 due-trials
Listed as ongoing, but also has a completion date and reported results 2011-005422-21 A Phase 3, Open-Label Study with Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who Are Null or Partial Responders to Peginterferon ... 2013-12-09 bad-data
Reported results 2011-005446-35 A Phase 3 Study with Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naive Subjects ... 2014-09-29 due-trials
Reported results 2011-006180-21 A PHASE IV, OPEN-LABEL, MULTICENTER STUDY OF 2015-10-01 due-trials
Ongoing 2011-006181-41 An open label, randomized (2:1) Phase 2b study of Dasatinib vs. Imatinib in patients with Chronic Phase Chronic Myeloid Leukemia who have not achieved an optimal response to 3 months of therapy with ... not-yet-due
Reported results Terminated 2011-006187-47 A 48-Week, Randomized, Open-Label Phase 3b Study Comparing the Antiviral Efficacy and Safety of ATV/RTV Plus 3TC with ATV/RTV plus TDF/FTC in HIV-1-Infected, Treatment-Naive Subjects, Followed by a 48... 2012-12-05 due-trials
Reported results 2011-006323-37 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Triple Therapy with Saxagliptin added to Dapagliflozin in Combination ... 2015-01-12 due-trials
Reported results 2011-006324-20 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy with Dapagliflozin added to Saxagliptin in Combination with Me... 2015-02-19 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-000070-28 A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Treatment-Naive Subjects or Null Responders to Prior Peginterferon Alfa (PegIFN)/R... 2013-11-21 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-000509-54 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2B Trial to Evaluate the Safety and Efficacy of BMS-823778 in Overweight and Obese Subjects with Inadequately Control... 2012-11-12 bad-data
Reported results 2012-000679-18 A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Add-On Therapy with Saxagliptin and Dapagliflozin added to Metformin co... 2014-01-17 due-trials
Trial is partly outside EEC, and reported results 2012-000714-11 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil (MMF) and Corticosteroids... 2018-05-30 bad-data
Listed as ongoing, but also has a completion date 2012-001314-42 Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (belatacept)-based Immunosuppression 2019-10-24 bad-data
Ongoing 2012-001421-27 Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE not-yet-due
Exempt 2012-001514-42 A Phase I-II Dose Escalation and Expansion Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (... not-yet-due
Trial is outside EEC 2012-001581-15 Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects at Risk for a Venous or Arterial Thrombotic Disorder bad-data
Ongoing 2012-001828-35 A Randomized Open-Label Phase 3 Trial of BMS-936558 versus Investigator’s Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy not-yet-due
Trial is outside EEC 2012-001840-23 An exploratory study of the biologic effects of Nivolumab and Ipilimumab Monotherapy and Nivolumab in Combination with Ipilimumab Treatment in Subjects with Advanced melanoma (Unresectable or metastat... bad-data
Trial is partly outside EEC, and reported results 2012-002249-39 Phase 2 Study of Ipilimumab in Children and Adolescents (12<18 years) with Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma 2016-07-07 bad-data
Ongoing 2012-002472-14 An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small cell Lung Cancer (NSCLC) not-yet-due
Ongoing 2012-002798-80 A Phase 3 Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults with Active Psoriatic Arthritis not-yet-due
Trial is partly outside EEC, and reported results 2012-003195-39 A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents with Active Polyarticular Juvenile ... bad-data
Listed as ongoing, but also has a completion date and reported results 2012-003280-22 Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment naïv... 2015-08-27 bad-data
Reported results 2012-003291-38 A Randomized, Open-Label, Multicenter Phase II Study of Ipilimumab Retreatment versus Chemotherapy for Subjects with Advanced Melanoma who Progressed after Initially Achieving Disease Control with Ipi... 2014-07-04 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-003463-22 A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV in Treatment Naïve Subjects with Chronic HCV Infection, who have Underlying Mild or Moderate Hemophilia or Patients who are Prior Rela... 2015-01-22 bad-data
Reported results 2012-003508-11 A Double-Blinded, Randomized Control Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a Compared to Peginterferon alfa-2a, Each in Combination with Ribavirin, in the Treatment of Naiv... 2014-09-18 due-trials
Ongoing 2012-003718-16 A Phase 3, Randomized, Double-Blind Study of BMS-936558 (Nivolumab) vs Dacarbazine in Subjects with Previously Untreated, Unresectable or Metastatic Melanoma not-yet-due
Ongoing 2012-003965-16 A Single-Arm Phase 2 Study of BMS-936558 in Subjects with Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens not-yet-due
Reported results 2012-004124-38 Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 with Atazanavir +/- Ritonavir (Open-Labe... 2014-11-29 due-trials
Ongoing 2012-004502-93 An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer not-yet-due
Reported results 2012-004531-23 A 24-Week International, Multi-center, Randomized, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adult Su... 2016-06-01 due-trials
Reported results 2012-005093-54 A Double-Blind, Placebo-Controlled, Randomized, Twostage, Parallel-Group, Adaptive Design Phase 2a Study to Evaluate the Effects of BMS-813160 in Subjects with Type 2 Diabetes Mellitus and Diabetic Ki... 2015-06-12 due-trials
Ongoing 2012-005371-13 A Phase 3, Randomized, Double- Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab Versus Ipilimumab Monotherapy in Subjects with Previously Untreated, Unresectable or Metastati... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2013-000055-41 Assessment of an Education and Guidance programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) 2016-02-01 bad-data
Not reported 2013-002090-21 2013-002090-21 2019-02-05 due-trials
Ongoing, reported early 2013-002458-66 A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Subjects with Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis not-yet-due
Ongoing, reported early 2013-002468-20 A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects with Genotype 1 Chronic Hepatitis C not-yet-due
Exempt 2013-002844-10 A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors not-yet-due
Ongoing 2013-003621-28 A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) o... not-yet-due
Listed as ongoing, but also has a completion date 2013-003622-86 An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) 2007-11-26 bad-data
Ongoing 2013-003645-42 A single arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL) not-yet-due
Ongoing 2013-003738-34 A Randomized Phase 2b, Open Label Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM) Revised Protocol 01, incorporati... not-yet-due
Reported results 2013-003780-65 A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects with Moderate to Severe Active Rheumatoid Arthritis who have Exp... 2015-06-17 due-trials
Ongoing 2013-003939-30 A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer not-yet-due
Reported results 2013-005487-26 A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 I... 2017-08-21 due-trials
Trial is partly outside EEC 2014-000328-47 A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy ... bad-data
Reported results 2014-001231-36 A phase IV trial to assess the effectiveness of Apixaban compared with usual care anticoagulation in subjects with non-valvular Atrial Fibrillation undergoing cardioversion 2017-02-08 due-trials
Ongoing 2014-001285-10 An Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) Monotherapy in Subjects with Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) who Have Received at Le... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2014-001286-28 A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS- 936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Treat... 2019-01-18 bad-data
Reported results 2014-001429-33 Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy 2018-01-22 due-trials
Ongoing 2014-001509-42 Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects not-yet-due
Ongoing 2014-001750-42 A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma not-yet-due
Listed as ongoing, but also has a completion date and reported results 2014-002004-24 An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation a... 2018-11-10 bad-data
Ongoing, reported early 2014-002111-41 A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068/GSK3684934 in Heavily Treatment Experienced Subjects Infected with Mu... not-yet-due
Reported results 2014-002184-14 A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BMS-931699 vs. Placebo on a Background of Limited Standard of care in the Treatment o... 2017-10-26 due-trials
Exempt 2014-002241-22 A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkin... 2019-05-24 not-yet-due
Trial is partly outside EEC 2014-002351-26 A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for ... bad-data
Exempt 2014-002372-89 A Phase 1/2 Multicenter Study of BMS-986012 in Subjects with Relapsed/Refractory Small Cell Lung Cancer not-yet-due
Exempt 2014-002485-70 A Phase I/IIa Study of BMS 986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects with Select Advanced Solid Tumors 2019-05-27 not-yet-due
Reported results 2014-002604-25 Randomized, Multicenter, Double- Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subject... 2018-05-03 due-trials
Exempt 2014-002605-38 A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Mo... not-yet-due
Trial is partly outside EEC 2014-002606-20 A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT bad-data
Reported results 2014-002987-34 A Phase 2, Randomized, Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who are Asymptomat... 2016-12-15 due-trials
Ongoing 2014-003282-19 An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in relapsed and refractory Multiple Myeloma. not-yet-due
Ongoing 2014-003625-17 A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent not-yet-due
Ongoing 2014-003626-40 A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma not-yet-due
Ongoing 2014-003630-23 An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-N... not-yet-due
Trial is outside EEC 2014-003963-39 An In Vitro Comparison of Apixaban Activity in Adult and Pediatric Plasma bad-data
Ongoing 2014-004278-40 Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib not-yet-due
Trial is outside EEC, and reported results 2014-005134-64 Phase I/II Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, ATAZANAVIR, ATV, REYATAZ™) in Combination Regimens in Antiretroviral Therapy (ART)-Naïve and Experien... bad-data
Ongoing, reported early 2014-005310-28 Open-Label, Randomized Study of Daclatasvir, Sofosbuvir, and Ribavirin for 12 vs. 16 weeks in Treatment-Naïve and Treatment-Experienced Patients with Genotype 3 Chronic Hepatitis C Infection with Comp... not-yet-due
Exempt 2015-000230-29 Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab and Nivolumab plus Ipilimumab in Subjects with Virus-Positive and Virus-Negative Solid Tumors not-yet-due
Exempt 2015-000324-29 A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the not-yet-due
Ongoing 2015-001097-18 An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy not-yet-due
Ongoing 2015-001274-17 Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV... not-yet-due
Listed as ongoing, but also has a completion date 2015-001275-50 A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remi... 2020-03-10 bad-data
Ongoing 2015-002441-61 A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lun... not-yet-due
Exempt 2015-002505-11 A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Anti... 2019-12-16 not-yet-due
Ongoing 2015-002740-13 A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma not-yet-due
Listed as ongoing, but also has a completion date and reported results 2015-002887-17 Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety/Pharmacokinetics of BMS-986142 in Subjects with Moderate to... 2018-05-03 bad-data
Ongoing 2015-003286-28 A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression not-yet-due
Ongoing 2015-003339-36 A Multicenter, Randomized, Open-label Study in Patients with esophageal Cancer refractory or intolerant to Combination Therapy with Fluoropyrimidine and Platinum-based Drugs not-yet-due
Ongoing 2015-003739-37 A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor 06-methylguanine DNA methy... not-yet-due
Reported results Terminated 2015-003959-22 A Phase 2, Placebo Controlled, Randomized, Double-Blind, Parallel-Arm Study to Evaluate Efficacy and Safety of BMS-986141 For the Prevention of Recurrent Brain Infarction in Subjects receiving acetyls... 2017-02-21 due-trials
Ongoing 2015-004633-27 A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4... not-yet-due
Ongoing 2015-004722-34 A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA met... not-yet-due
Exempt 2015-004816-39 A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination with Nivolumab or Ipilimumab in Advanced Solid Tumors not-yet-due
Exempt 2015-004914-79 A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in A... not-yet-due
Ongoing 2015-004920-67 Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination with Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination with Ipilimumab 3 mg/kg in Subjects with Previously Unt... not-yet-due
Trial is outside EEC 2015-005450-36 A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms With Switchover, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndro... bad-data
Ongoing 2015-005556-10 A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer not-yet-due
Ongoing 2015-005699-21 An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma not-yet-due
Reported results 2016-000101-37 A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Subjects with Moderate to Severe Primary Sjö... 2017-07-24 due-trials
Ongoing 2016-000461-23 An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies not-yet-due
Exempt 2016-000603-91 A Phase 1/2a Study of BMS-986179 Administered alone and in Combination with Nivolumab (BMS- 936558) in Subjects with Advanced Solid Tumors. not-yet-due
Ongoing 2016-000725-39 An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in ... not-yet-due
Ongoing 2016-000894-19 A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL) not-yet-due
Trial is outside EEC, and reported results 2016-000940-32 A Phase III, Multicenter, Open-Label Study to Assess Efficacy, Safety, Pharmacokinetics and Immunogenicity of Abatacept Administered Intravenously in Japanese Children and Adolescents with Active Juve... bad-data
Ongoing 2016-001018-76 A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subject... not-yet-due
Other 2016-001247-39 A Prospective, Randomized, Open Label, Multi-center Study of the Safety and Pharmacokinetics of Apixaban versus Vitamin K Antagonist or LMWH in Pediatric Subjects with Congenital or Acquired Heart Dis... not-yet-due
Exempt 2016-001359-36 A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors not-yet-due
Ongoing 2016-001514-20 A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or M... not-yet-due
Ongoing 2016-001645-64 A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma... not-yet-due
Listed as ongoing, but also has a completion date 2016-001654-18 A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys with Duchenne Muscular Dystrophy 2019-11-04 bad-data
Listed as ongoing, but also has a completion date 2016-001685-29 A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging, Phase 2b Study of the Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of BMS-986231 in Hospit... 2019-11-12 bad-data
Exempt 2016-001692-67 A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer not-yet-due
Completed, report not yet due 2016-001835-11 A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung) Revised Lung Master Protocol: 07 (revprot07)... 2020-01-29 not-yet-due
Ongoing 2016-001859-43 A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma not-yet-due
Ongoing 2016-001928-54 A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer not-yet-due
Completed, report not yet due 2016-001941-26 Phase IIIb, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects with Previously Untreated Unresectable or Metastatic Melanoma 2019-10-25 not-yet-due
Not reported Terminated 2016-001948-19 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Primary Sjögrens Syndrome 2018-12-03 due-trials
Ongoing 2016-002269-77 A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adu... not-yet-due
Trial is partly outside EEC 2016-002347-41 Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin ly... bad-data
Reported results 2016-002481-31 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis 2017-11-16 due-trials
Listed as ongoing, but also has a completion date 2016-002554-21 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB0092 in Participants with Progressive Supranuclear Palsy 2019-12-13 bad-data
Ongoing 2016-002621-10 A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Advanced Malignancies not-yet-due
Ongoing 2016-002807-24 A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Gastric Cancer not-yet-due
Trial is partly outside EEC 2016-002898-35 A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (T... bad-data
Ongoing 2016-003082-26 A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma not-yet-due
Ongoing 2016-003536-21 Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC not-yet-due
Ongoing 2016-003586-26 A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Cross-over Phase 2 Study of Continuous 5-Hour Intravenous Infusions of BMS-986231 in Patients with Heart Failure and Impaired S... not-yet-due
Other 2016-003729-41 A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma... not-yet-due
Ongoing 2016-003881-14 A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab or with Standard of Care Chemotherapy versus Standard of Care Chemotherapy in Participants with Previously Untreated Unres... not-yet-due
Trial is partly outside EEC 2016-004441-82 Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies bad-data
Ongoing 2016-004502-34 A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial ... not-yet-due
Exempt 2017-000238-73 A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 (anti-ICOS mAb) Alone or in Combination with Nivolumab or... not-yet-due
Exempt 2017-000367-33 Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined with Daratumumab in Participants with Advanced or Metastatic Solid Tumors not-yet-due
Exempt 2017-000597-11 Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors. not-yet-due
Ongoing 2017-000759-20 A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advan... not-yet-due
Ongoing 2017-001195-35 A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) not-yet-due
Ongoing 2017-001203-79 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus not-yet-due
Ongoing 2017-001626-17 A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer not-yet-due
Exempt 2017-001725-40 A Phase 1b/2 Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors. not-yet-due
Ongoing 2017-001976-48 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS 986165 in Subjects with Moderate-to-Severe Crohn's Disease not-yet-due
Trial is partly outside EEC 2017-002499-14 A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined with Nivolumab versus Nivolumab in Participants with Metastatic or Unresectable Melanoma that is Previously Untreated bad-data
Ongoing 2017-002672-38 Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cance... not-yet-due
Listed as ongoing, but also has a completion date 2017-002676-87 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab plus Cisplatin, in Combination with Radiotherapy in Participants with Cisplatin Ineligible and Cisplatin Eligibl... 2019-10-14 bad-data
Ongoing 2017-002755-29 A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Abl... not-yet-due
Not reported 2017-003059-46 A Randomized, Global, Open-label Study of Nivolumab in Combination with BMS-986205 vs Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck 2018-09-04 due-trials
Trial is partly outside EEC 2017-003338-94 Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics, Safety and Efficacy of Daclatasvir (DCV) in Combination with Sofosbuvir (SOF) in Children from 3 to less than 18 Years of Age with GT-1 t... bad-data
Ongoing 2017-003581-27 A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cance... not-yet-due
Ongoing 2017-003583-12 A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma not-yet-due
Ongoing 2017-003662-27 An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer not-yet-due
Ongoing 2017-004692-31 A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy with Nivolumab or... not-yet-due
Listed as ongoing, but also has a completion date 2017-004896-30 A Randomized, Active-Controlled, Blinded, Phase III Clinical Trial of BMS- 986213 (Fixed Dose Combination of Relatlimab [anti-LAG-3] and Nivolumab) in Combination with Chemotherapy versus Placebo in C... 2018-10-02 bad-data
Ongoing 2017-005029-19 A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarctio... not-yet-due
Ongoing 2018-000040-26 A Phase 3b Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H)... not-yet-due
Exempt 2018-000058-22 A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with... not-yet-due
Ongoing 2018-000339-28 A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination with Nivolumab (BMS-936558) with and without chemotherapy in Patients with Advanced Pancreatic Cancer not-yet-due
Exempt 2018-000340-26 A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers not-yet-due
Exempt 2018-000416-21 A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors not-yet-due
Ongoing 2018-000462-11 An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC) not-yet-due
Completed, report not yet due 2018-000970-31 A Randomized, Double-Blind, Placebo-Controlled, Cross-over Phase 2 Study of Continuous 8 Hour Intravenous Infusions of BMS-986231 in Patients with Heart Failure and Impaired Systolic Function Given a ... 2020-01-09 not-yet-due
Exempt 2018-001030-17 Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies not-yet-due
Ongoing 2018-001069-18 A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) and Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment in... not-yet-due
Completed, report not yet due Terminated 2018-001070-20 A Randomized, Active-Controlled, Open-Label, Phase 2 Clinical Trial of BMS-986213, in Combination with Various Standard-of-Care Therapeutic Regimens, in Participants with Recurrent, Locally Advanced, ... 2019-05-16 not-yet-due
Trial is partly outside EEC 2018-001423-40 A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma bad-data
Exempt 2018-001585-42 Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy not-yet-due
Ongoing 2018-001925-24 A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjec... not-yet-due
Ongoing 2018-001926-25 A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis not-yet-due
Exempt 2018-002108-15 Phase 1/2 Study of BMS-986310 Administered Alone and in Combination with Nivolumab in Participants with Advanced Solid Tumors not-yet-due
Ongoing 2018-002676-40 A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisp... not-yet-due
Ongoing 2018-003471-35 A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus not-yet-due
Ongoing 2018-004142-42 A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis not-yet-due
Ongoing 2018-004293-10 A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects with Active Psoriatic Arthritis (PsA) not-yet-due
Ongoing 2018-004362-34 Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab not-yet-due
Ongoing 2018-004694-27 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis not-yet-due
Ongoing 2018-004695-35 A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or ... not-yet-due
Ongoing 2019-000252-34 A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma not-yet-due
Ongoing 2019-000262-38 A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab ... not-yet-due
Ongoing 2019-000612-29 An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis not-yet-due
Ongoing 2019-001222-98 A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followe... not-yet-due
Other 2019-001230-34 A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CheckMate 76K: CHECKpoint pathway and nivoluMAb clin... not-yet-due
Ongoing 2019-001334-34 Randomized, Non-comparative Neoadjuvant Phase II Study in Patients with ER+/HER2- Breast Cancer >= 2 cm with Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole not-yet-due
Ongoing 2019-002030-36 A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer not-yet-due
Ongoing 2019-002469-37 A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-... not-yet-due
Ongoing 2019-002567-96 A phase 3, randomized, double-blind trial of nivolumab in combination with intravesical BCG versus standard of care BCG alone in participants with high-risk non-muscle invasive bladder cancer that is ... not-yet-due

Related organisations

Over time organisations can merge, or split.

We think Bristol-Myers Squibb is now also responsible for the trials of: